A new generative artificial intelligence (AI) tool has been launched by H1, a global healthcare data company and will have a 'profound impact on clinical trial diversity'.
A 15-year partnership between Medidata, a Dassault Systèmes company, and the National Cancer Institute (NCI) has been extended by five years. The NCI is part of the National Institutes of Health.
At DPharm 2023, there was a huge meeting of minds to discuss the latest innovations in clinical trials. Outsourcing Pharma was delighted to have an in-depth discussion with IQVIA’s Elan Josielewski, senior principal and head of operations, patient centered...
Drug discovery will benefit from a virtual artificial intelligence (AI) expert thanks to Opportunity Pharma and OpenEye, Cadence Molecular Sciences joining forces.
Mural Health Technologies, Inc. has raised $8 million in seed funding for the growth of its Mural link platform it says is aimed at ‘modernizing the clinical trial experience for both patients and caregivers’.
Built upon seven years of real-world patient journey data, Belong.Life has recently announced the launch of its software as a service (SaaS)-based conversational artificial intelligence (AI) cancer clinical trial matching platform.
Andrew MacGarvey is chief operating officer (COO) of Phastar. We caught up with him earlier in the summer at DIA Global in Boston to discuss the company’s origins, opportunities for big analytical data DCTs, artificial intelligence and machine learning...
Emerald Cloud Lab (ECL) was the world’s first highly automated cloud laboratory, was set up by two friends, Brian Frezza and D.J Kleinbaum who grew up together and joined forces after their PhDs to found the company.
A partnership between Banner Health and nference will offer more ‘potent insight generation, offering researchers the option to examine more inclusive data’.
QuantHealth announced it has raised a $15 million series A funding round today (August 22) for its clinical simulator that can predict how a patient will respond to treatment in a clinical trial.
Another company OSP was lucky enough to catch up with at DIA Global in Boston this year, was well-established generative artificial intelligence (AI) software company, Yseop.
Rohit Nambisam is CEO of Lokavant, OSP caught up with him at DIA Global in Boston earlier this summer to find out more about him and the work he is passionate about.
Healthcare technology company Koneska is extending its contribution to critical neuroscience research by collaborating with an academic partnership program.
A partnership between technology company Fluree and Vitality TechNet is a ‘groundbreaking effort’ to shorten timelines within the drug discovery process.
Nathan Johnson has 20 years’ experience in clinical research as an innovator and programmer with expertise in statistical analysis and reporting, SAS programming, standards development, and data management.
OSP was fortunate enough to have an interesting discussion with Stephen Corson, who is a statistics manager at Phastar, a specialist biometrics CRO headquartered in the UK.
A company that ‘translates science into survival’ by developing new therapies has completed its acquisition of a technology company leading in artificial intelligence (AI) and machine learning (ML).
Greenphire, provider of clinical trial financial solutions, has released its global 2023 State of Clinical Trial Patient Convenience Market Trends survey.
Jason Dong, co-CEO-founder of Mural Health, wants to make sure patients taking part in trials are not out of pocket. He joined OSP while at DIA Global to discuss how his business came about and why it is so important.
Updated guidelines for risk-based quality management (RBQM) are much more than just for monitoring purposes and can show quality by design concepts, save immeasurable time on manpower and shows there has been a complete mindset shift within the last 15...
OSP spoke to senior director of clinical trials, Erin Leckrone, and Kathleen Kane, senior manager of clinical operations at Be The Match Biotherapies, to discuss how creating a well-designed and reviewed protocol is critical to a study's overall...
With the FDA issuing guidance on more diversity within clinical trials, it is a subject many companies are being encouraged to focus on, each with their own approach.
RAIR Health, an applied data and AI company focused on the extraction of clinical insights from real world data, has signed a non-exclusive data license agreement with Royal Cornwall Hospitals NHS Trust (RCH) focussed on the field of ophthalmology.
uMotif is starting to reap the rewards of its patient first technology – that really does what it says on the tin, says the company’s CEO, Steve Rosenberg.
Everybody seems to be talking about artificial intelligence at the moment. Some are fascinated, others afraid and a few might worry for their jobs. However, for the pharmaceutical industry, it is said to be completely transforming the landscape.
Helmholtz Munich, part of Germany’s biggest research organization, the Helmholtz Association, alongside DDN, the world’s largest data storage company have been selected as a winner of the 2023 AI Breakthrough Awards, for best AI-based solution for life...
The digital biomarkers company has partnered with Beacon Biosignlas, a computational neurodiagnostics company to launch a clinical trial investigate the integration of Beacon’s at-home electroencephalogram (EEG) into Koneksa’s neuroscience solution toolkit.
A statistics manager at specialist biometrics contract research organization (CRO) Phastar, has been chosen to receive the DIA 2023 Global Inspire Award for Community Engagement.
Phastar is a specialist biometrics contract research organization offering statistical consulting, clinical trial reporting, data management and data science services and will be providing a presentation and running a workshop to give delegates working...
Slope, a site-first organization, ‘eliminating the chaos’ impacting clinical trials has joined CancerX as a founding member of The White House’s national Cancer Moonshot.
Adede is a seasoned computer scientist and data professional known for providing high quality service whilst employing her multi talents which include efficiency, analytical thinking, and fast learning.
With generative AI continuing to create a buzz, OSP took the opportunity to speak to Indegene, a digital-first, life sciences commercialization company that helps biopharmaceutical, emerging biotech and medical device companies develop products. Talking...
A healthcare company on a mission to produce a multi-cancer early detection (MCED) test so patients have more chance of being cured, has produced 'exciting results' from a study.
Research has reinforced the efficacy of Lumakras (sotorasib), a small molecule inhibitor in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).
'Compelling and landmark' results will ‘fundamentally change’ the journey of patients with stage 2 and 3 early breast cancer, specifically those in need of new, well-tolerated options to prevent their cancer from coming back.
The US Food and Drug Administration will soon require researchers and companies seeking approval for late-stage clinical trials to submit a diversity plan for trial participants. Scott Gray, CEO of Clincierge, discusses how trial sponsors and CROs can...
The UK has the tools to become a life-sciences superpower but those thinking about taking part remain put off by the lack of financial motivation, a clinical trials start-up says.
With an increase in clinical studies demanding an increase in CRAs, we spoke to Sara Brannon, director of quality and training development, at ICON, to find out their approach to recruiting and how the industry is suffering due to a global shortage because...
Cognizant has announced a platform that can use it consulting, advisory, ecosystem partnership along with digital studios and industry knowledge to help its clients transition to generative artificial intelligence (AI).
Helmholtz Munich, one of Germany’s 19 research centers, that develops future solutions and technologies has selected DataDirect Networks (DDN) to accelerate its artificial intelligence (AI) driven discoveries.
AARDEX Group has joined forces with other industry companies to partner with a new project from The Digital Medical Society (DiMe) called Extending the Verification, Analytical Validation, and Clinical Validation – or V3+ Framework.
Results from a multinational trial of trifluridine/tipracil, known as Lonsurf, with or without bevacizumab in refractory metastatic colorectal cancer (mCRC) have resulted in statistically significantly and clinically meaningful improvements.
